What is the recommended treatment for Trichomonas vaginalis infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Trichomonas Vaginalis

Treat trichomoniasis with oral metronidazole 500 mg twice daily for 7 days in women, or metronidazole 2 g as a single oral dose in men. 1

Primary Treatment Recommendations

For Women

  • Preferred regimen: Metronidazole 500 mg orally twice daily for 7 days 1
  • Alternative regimen: Metronidazole 2 g orally as a single dose 2, 3

The 7-day regimen is superior for women based on a 2018 randomized controlled trial that demonstrated significantly lower treatment failure rates (11% vs 19%, p<0.0001) compared to single-dose therapy 1. This represents the most recent high-quality evidence and should guide treatment decisions for women.

For Men

  • Preferred regimen: Metronidazole 2 g orally as a single dose 4
  • Alternative regimen: Metronidazole 500 mg orally twice daily for 7 days 2, 3

Treatment Efficacy

Both regimens achieve cure rates of approximately 90-95% when used appropriately 2, 3, 5. The key difference is that multi-dose therapy performs better in women, while single-dose therapy remains adequate for men.

Critical Management Points

Partner Treatment

Always treat sexual partners concurrently, even without testing 2, 3. This is essential because:

  • Partner treatment increases cure rates
  • Prevents reinfection
  • Reduces transmission
  • Instruct patients to avoid sexual contact until both partners complete therapy and are asymptomatic

Treatment Failure Protocol

If initial treatment fails, follow this escalation algorithm 2, 3, 5:

  1. First failure: Re-treat with metronidazole 500 mg twice daily for 7 days
  2. Second failure: Metronidazole 2 g once daily for 3-5 days
  3. Persistent failure: Consult infectious disease specialist and obtain susceptibility testing (CDC consultation available at 770-488-4115)

Special Populations

Pregnancy

  • Any trimester: Metronidazole 2 g single dose is safe and recommended 3, 5
  • Treating symptomatic trichomoniasis in pregnancy is warranted to prevent preterm birth, premature rupture of membranes, and low birthweight 5, 6
  • Multiple studies have not demonstrated teratogenic or mutagenic effects from metronidazole use during pregnancy 5
  • Note: Older 1993 guidelines contraindicated first-trimester use 2, but this has been superseded by more recent evidence showing safety

HIV-Infected Patients

Treat with the same regimens as HIV-negative patients 2, 3, 5. However, HIV-infected women may benefit from the 7-day regimen given higher treatment failure rates in this population 7.

Metronidazole Allergy

  • No effective alternatives exist 2, 3
  • Desensitization is the only option for true allergy 3, 5
  • Topical therapies have cure rates <50% and are not recommended 5

Important Caveats

Do NOT Use Topical Metronidazole

Metronidazole gel (approved for bacterial vaginosis) has efficacy <50% for trichomoniasis because it cannot achieve therapeutic levels in the urethra or perivaginal glands 3, 5. Only oral metronidazole is effective.

Follow-Up Testing

  • Routine test-of-cure is NOT recommended for asymptomatic patients after treatment 2, 3, 6
  • Rescreening at 3 months is recommended due to high reinfection rates 4
  • Only perform test-of-cure if symptoms persist

Antimicrobial Resistance

Metronidazole resistance occurs in approximately 4-5% of cases 4, 7, 8. Most resistant strains respond to higher doses using the treatment failure protocol above. True resistance requiring susceptibility testing is rare but increasing.

Clinical Presentation

Women typically present with malodorous yellow-green discharge and vulvar irritation, while most men are asymptomatic 2, 3. The infection is associated with increased HIV acquisition risk, cervical cancer, and adverse pregnancy outcomes 4, 7.

References

Research

Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2015

Research

A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.